A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes.

Trial Profile

A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Dec 2010

At a glance

  • Drugs Gemigliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Sep 2010 Results were reported at the 46th Annual Meeting of the European Association for the Study of Diabetes.
    • 13 Jul 2010 New trial record
    • 25 Jun 2010 Results have been presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA 2010).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top